LONDON and WILMINGTON, N.C., Dec. 10, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Dr. Cedric Burg and James Gunter have joined Chiltern, bringing their expertise in clinical research to serve our clients' needs and to strengthen our Global Clinical Development services.
"It gives me great pleasure to announce that Dr. Cedric Burg has been appointed to the position of Vice President, Global Clinical Development, Americas," stated Aize Smink, Chief Operating Officer, Chiltern. "Cedric will head Chiltern's Global Clinical Development business in the Americas, where he will lead our teams in Latin and North America to continue the expansion of our services and capabilities. We believe that Cedric's international experience and exposure to both pharma and CROs will be of great value to our clients in the US and ROW."
Recently joining Chiltern is James Gunter as Director of Dedicated Biometrics Services. "I am pleased to announce James Gunter as an addition to our Chiltern Biometrics team," commented Alecia Barbee, Vice President, Global Biometrics, Chiltern. "James will head up the Biometrics FSPs globally, where his industry experience and client focus will lead this team in continued growth."
Dr. Cedric Burg has more than 17 years experience in the clinical research field and has a truly international profile having held global senior roles within both a CRO environment and Pharma. He holds a Master's degree in Life and Health Sciences from the Universite de Rennes I, France, and a doctorate in Molecular and Cellular Biology from the Universite de Nantes, France, and will be based out of Wilmington, NC, US.
James Gunter brings 16 years in life sciences experience, including 12 years in operational and management roles in the CRO industry. He has spent most of his career leading Biometrics and Information Technology teams globally in the Americas, Europe and Asia. In these roles, he has been responsible for building teams and implementing processes and technologies that improve the efficiency and quality of clinical trials. James is field-based in the US.
Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,400 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com. For More Information Contact:Natalie Chong
Susan OjanenMarketing Director
Marketing ExecutiveChiltern International Ltd.
Chiltern International Inc.171 Bath Road
1241 Volunteer ParkwaySlough
Suite 950Berkshire SL1 4AA
Bristol, TN 37620UNITED KINGDOM
USATel: +44 (0) 1753 512 000
Tel: +1 (423) 968 firstname.lastname@example.org
Copyright©2012 PR Newswire.
All rights reserved